skip to Main Content
Register now with early fees
Add to Calendar 02/24/2022 13:00 02/25/2022 17:30 MM/DD/YYYY Europe/Zurich Viral Hepatitis Elimination 2022 Brussels, Belgium

Viral Hepatitis Elimination 2022 scientific programme

Browse the full programme

Session 1: Introduction and aims of the conference

The WHO goal of eliminating viral hepatitis has led to a surge in activities to achieve a world free from viral liver disease. International experts will discuss optimal approaches to eliminate viral liver disease and to assess progress towards elimination. The conference will aim to provide guidance and recommendations to those working towards elimination of hepatitis b and hepatitis C.

Session 2: Assessing the burden of hepatitis B and C

This session will provide a critical assessment of the methodology currently used to measure incidence, prevalence, and health burden (both morbidity and mortality) of viral hepatitis. In particular, during a dedicated panel discussion, both model-based and population sampling-based estimates will be compared, and their advantages and limitations critically analysed. An additional discussion will be devoted to the clinical impact of comorbidities in patients both living with chronic hepatitis B and taking antiviral therapy.

Session 3: Hepatitis B and D

Transmission of the hepatitis B virus (HBV) occurs mainly perinatally and during early childhood in highly endemic areas, but more often by sexual contact or through contaminated needles in low endemic areas. Universal vaccination of all infants as soon as possible after birth (preferably within 24 hours, followed by two or three doses, four weeks apart) is the most feasible and cost-effective strategy for HBV infection control. Furthermore, the HBV vaccine is the mainstay of both hepatitis B and D prevention. According to WHO estimates, the proportion of children under five years of age chronically infected with HBV dropped to just under 1% in 2019, down considerably from around 5% in the pre-vaccine era (ranging from the 1980s to the early 2000s). This marks the achievement of one of the milestone targets to eliminate viral hepatitis in the Sustainable Development Goals.

However, the coverage of HBV vaccine at birth remains uneven. It is  particularly low in the African region, where the HBV burden is currently higher, thus alternative policies to overcome the barriers to vaccination need to be identified. Antiviral therapy serves to limit HBV infection spreading from highly viremic HBsAg-positive mothers and in the setting of high-risk groups (such as prisoners, people who inject drugs, and people with multiple sex partners). Individualised antiviral therapy, however, is currently an unmet need. New algorithms and/or models of circulating biomarkers to simulate the dynamics of the HBV and host interplay and to tailor different combinations of antiviral drugs to the different clinic-pathologic conditions of the individual patient need to be developed. Likewise, surrogate markers of off-treatment sustained response are needed to enable a safe withdrawal of treatment. In patients with chronic hepatitis D, it is essential to identify key HBV helper functions (such as viral proteins production vs viral replication) as target of antiviral therapy, in order to reach optimal control of both HBV and HDV infections.

Session 4. Viral Hepatitis in a world of big data 

This session will explore the multifaceted issue of data in the context of hepatitis elimination. High-quality data on viral hepatitis is scarce and there is a need for better-quality data to improve patients’ health outcomes. Factors such as the privacy and security of this data must also be guaranteed. In this session, data collection, both at European level and internationally, will be discussed as well as the opportunities and challenges relating to a uniform European-wide collection system. One discussion will focus on vulnerable populations who are most heavily affected by hepatitis, such as people living in institutionsand pregnant women and their infants. Collecting data is critical to improve health in these populations, but data collection should be designed in a thoughtful manner that does not inadvertently harm vulnerable populations. 

Session 5: Equalising chances

The COVID-19 pandemic has severely impacted the scaling-up of viral hepatitis screening and treatment programmes worldwide, especially in at-risk populations who appear to be intrinsically vulnerable to severe forms of COVID-19, as a compounding of social vulnerability and comorbodities. Besides exploring the specific lessons to be drawn from COVID-19 and applicable to  hepatitis elimination, this session will address several aspects of inequalities with regards to hepatitis elimination, such as reasons for multiple treatment failure or the effects  of stigmatisation on the patient accepting their hepatitis diagnosis. The road to an HCV vaccine will also be explored as one of the responses to hepatitis elimination.

Session 6: Special populations

Viral hepatitis disproportionally affects the most vulnerable, marginalised, and underserved populations. As they often face the greatest challenges in accessing necessary services, because of social and structural barriersthese populations are often lost to follow-up along the continuum of care and have poorer health outcomes. Moreover, the marginalisation of key populations heightens the epidemic and diminishes efforts towards the WHO goal of elimination of viral hepatitis by 2030. This session will address pressing gaps and potential solutions for these populations, such as the managing of viral hepatitis in migrants and expanding the provision of hepatitis C services for men who have sex with men. Furtherthe session will explore how to reach the population of former drug users, and the possibilities of eliminating viral hepatitis in prisons. 

Session 7: Future challenges and opportunities

Has the COVID-19 pandemic cast doubt on the WHO's target to eliminate hepatitis by 2030? Despite alarming trends underway showing a decline in patient testing and treatment for hepatitis B and C, can we identify aspects of the COVID-19 response that could potentially improve hepatitis care? What are the responses from the pharmaceutical industry to these currents challenges and where do they see opportunities for improvement? The answers to these questions, and more, will be discussed with industry representatives, including from Gilead.

Session 8: Open discussion with partners on leadership in awareness raising, advocacy, and efforts towards viral hepatitis elimination

To overcome the barriers to achieving viral hepatitis elimination, we must improve people’s access to treatment and care. To this end, all actors involved, including patient organisations, must work together and deliver care at the community level. In this session, we will discuss with key patient associations (Coalition for Global Hepatitis EliminationCorrelation NetworkEuropean Liver Patients’ AssociationEuropean Monitoring Centre for Drugs and Drug AddictionLiver Patients InternationalWorld Hepatitis Alliance) their efforts towards viral hepatitis elimination and access to care and how European authorities (WHO Europe, European Centre for Disease Prevention and Control, and the European Commission) may help.

Back To Top